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Abstract
A substantial literature describes the capacity of all addictive drugs to slow cell growth and
potentiate apoptosis. Flow cytometry was used as a means to compare two lineages of circulating
progenitor cells in addicted patients. Buprenorphine treated opiate addicts were compared with
medical patients. Peripheral venous blood CD34+ CD45+ double positive cells were counted as
haemopoietic stem cells (HSC's), and CD34+ KDR+ (VEGFR2+) cells were taken as endothelial
progenitor cells (EPC's). 10 opiate dependent patients with substance use disorder (SUD) and 11
non-addicted (N-SUD) were studied. The ages were (mean + S.D.) 36.2 + 8.6 and 56.4 + 18.6
respectively (P <0.01). HSC's were not different in the SUD (2.38 + 1.09 Vs. 3.40 + 4.56 cells/mcl).
EPC's were however significantly lower in the SUD (0.09 + 0.14 Vs. 0.26 + 0.20 cells/mcl; No. >
0.15, OR = 0.09, 95% C.I. 0.01–0.97), a finding of some interest given the substantially older age of
the N-SUD group. These laboratory data are thus consistent with clinical data suggesting
accelerated ageing in addicted humans and implicate the important stem cell pool in both addiction
toxicology and ageing. They carry important policy implications for understanding the fundamental
toxicology of addiction, and suggest that the toxicity both of addiction itself and of indefinite agonist
maintenance therapies may have been seriously underestimated.
Background
A significant literature describes the capacity of all addic-
tive drugs to slow cell growth [1-3] on the one hand and
to potentiate apoptosis[4-8] on the other. The stem cell
hypothesis of ageing suggests that ageing at the organis-
mal level is reflected by impaired cell health at the cellular
level including reduced function, reduced growth,
increased senescence, and cell loss by apoptosis, necrosis
and other pathways[9,10]. The often disorganized and
disheveled body habitus of many drug addicts is well
known as is their predisposition to a variety of unusual
disorders. Indeed the addiction literature features a variety
of disorders well known to occur in geriatric popula-
tions[11]. Data from our clinic and elsewhere suggests
that disorders common in aged populations occur at an
increased frequency in addicted populations. This applies
to osteoporosis[12,13] neuropsychiatric disorders[14-16]
depressed sperm counts[17,18] calcific arteriosclero-
sis[19] graying of the hair[20], and severe dental disor-
ders[21,22]. These problems have in common a failure in
stem cell physiology. The high mortality accompanying
chemical addictions is also well recognized[23,24].
The field of stem cell biology of course is burgeoning with
many investigations centred around a host of prospective
applications in regenerative medicine and including par-
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ticularly bone marrow transplantation, tissue regenera-
tion and immune and gene therapy. Several recent
developments make these advances of particular interest
to the field of addictive medicine particularly to its toxi-
cology. Stem cells exist at low frequency in the peripheral
circulating blood and may be quantitated there. Several
methods have been recently described for the quantita-
tion of various lines of stem and progenitor cells in
peripheral blood[25-27] a tissue which is regularly
accessed in routine clinical care. Secondly the endothelial
progenitor cell has been said to be of enormous impor-
tance to the regeneration of the vasculature and has be
noted to be a superior predictor of cardiovascular out-
comes including mortality than commonly used classical
cardiovascular risk factors[25]. Similarly counts of the cir-
culating osteoblastic progenitor cell has been shown to
correlate with bone density studies[27]. Finally the cellu-
lar theory of ageing suggests that stem cells and their
health should be a special focus of ageing medicine and
the deficits associated with ageing, and this has been con-
firmed by recent reports[28,29].
Therefore it seemed important to us examine the periph-
eral blood for circulating stem cell numbers in addicted
and control populations. The ability to quantitate many
different lines of tissue specific stem cells invites an
opportunity to quantitate any supposed progeroid (pro-
ageing) effect in a variety of tissues by relatively straight-
forward technical means. As our clinic sees both addicts
and non-addicts in a primary care setting this population
seemed to provide an ideal opportunity to test the
hypothesis. The present results were reported when to our
great surprise statistical significance and interesting results
were obtained in the initial pilot study with only two lines
of progenitor cells and very limited patient numbers.
Whilst the present report is clearly of a preliminary nature,
should its main findings be confirmed by more sophisti-
cated laboratory and clinical studies the implications are
potentially far reaching indeed. In suggesting that the tox-
icity of addiction has been in large measure understated,
it implies that the drug policy debate might be potentially
re-cast by emerging evidence; in suggesting that addictive
agents have a deleterious effect on cell growth and regen-
eration it implies that indiscriminate application of indef-
inite agonist therapies should be re-prioritized
downwards in treatment protocols; in noting that there
are indications that the integrity of DNA replication is
likely compromised by addiction it informs studies of
tumour development; and in directly implicating the clas-
sical receptor-ligand pathways of addiction in the biology
of ageing it suggests new pathways of investigation and
identification of drug targets for the treatment of classical
age related degenerative pathologies.
Methods
Patients
Patients were chosen from our normal clinical primary
care population. Medical patients were representative of
those seen typically in primary care clinics. Opiate
addicted patients are maintained on buprenorphine/
naloxone combination and are gradually reduced. They
are not in clinical withdrawal at any time. Blood was
obtained with patient consent. Blood was drawn for
standard clinical indications in the course of routine
patient care. Peripheral venous blood was sampled from
patients and processed fresh without storage by flow
cytometry. Absolute lymphocyte counts were taken, and
CD34+ CD45+ double positive cells were counted as hae-
mopoietic stem cells (HSC's), and CD34+  KDR+
(VEGFR2+) cells were denoted endothelial progenitor
cells (EPC's). Progenitor cells were standardized against
the lymphocyte fraction as these were believed to be of the
most appropriate nuclear cytoplasmic ratio.
Flow cytometry
0.5 ml Peripheral blood collected in EDTA TUBES (BD).
The samples were prepared for flow cytometry analysis
using the Coulter TQ-Prep. The samples were incubated
with the monoclonal antibodies – CD34 FITC (BD Cat
No. 348053);CD45 PC5 (ID Test PN IM2652); KDR anti-
hVEGF PE (R&D Systems Cat No. FAB 357P). 20 mcl of
antibodies were used in accordance with the manufac-
turer's instructions. Samples were run on the Beckman
Coulter EPICs XL-MCL flow cytometer. Histograms using
forward scatter/side scatter; CD45vCD34; CD34vKDR
were generated. The gating strategy employed was as fol-
lows. 3 histograms were set up. The first was CD45 V's side
scatter linear a rectilinear region (region A) set to include
all CD45 positive events. The second, CD34 V's side scat-
ter linear – was gated on region A. A rectilinear region
(region B) was set to include all CD34 positive events. The
third region CD34 V's KDR- was gated on A and B. A quad-
stat region was set up and the dual CD34/KDR population
reported.
The percentage of CD34+/KDR+ and CD34+/KDR- cells
was quantitated. 10,000 events were counted per sample.
Statistical Analysis
Categorical data were analyzed by the 2 tailed Fisher Exact
test. Continuous data was analyzed by the Student's T-test
where normally distributed. These results were verified by
non-parametric analyses such as Friedman ANOVA. On
occasion more sophisticated multiple regression tech-
niques were required as detailed in the text. P less than
0.05 was considered significant.Substance Abuse Treatment, Prevention, and Policy 2007, 2:19 http://www.substanceabusepolicy.com/content/2/1/19
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Ethical Approval
This study was approved by the Institutional review board
of the Southcity Medical Centre, which is a Human Ethics
Research Committee registered with the National Health
And Medical Research Council of Australia (No. 000409).
Results
Patient characterization
Patient demographic and medical characteristics are
shown in Table 1. 10 opiate addicted SUD and 11 non-
addicted (N-SUD) were studied. N-SUD were considera-
bly older than SUD (means + S.D. 36.20 + 8.61 and 56.36
+ 18.56 Student's T = 3.13, df = 19, P = 0.0054). All SUD
were male and 55% of N-SUD were male (Fisher Exact test
P = 0.035). All patients were of European – Australian eth-
nic background. In keeping with the younger age of the
SUD, this group was taller (179.30 + 11.61 Vs. 169.82 +
8.22 Student's T = -2.177, df = 19, P = 0.042283). As
shown the weight, BMI, systolic and diastolic blood pres-
sures were not different. Two patients in each group (20%
and 18%) had a remote history of cardiovascular disease
2–10 years before (sub-acute bacterial endocarditis and
insulin dependent diabetes mellitus; and multiple pulmo-
nary embolus and coronary heart disease, myocardial inf-
arction and hypertension respectively). The last
mentioned control patient was currently taking cardiovas-
cular medication.
Drug use
The drugs used by this group are described in Table 2. The
major drug of addiction for which treatment was sought
was opiates (heroin and morphine), but a variety of other
agents were commonly used by this cohort particularly
tobacco and cannabis and some stimulants as has been
previously reported21. As shown in the table, the SUD
group used significantly more tobacco, cannabis, amphet-
amine and heroin than N-SUD. The alcohol use rate was
not different, and none of the patients in either group had
a history of problematic alcohol consumption. Opiate
agonist pharmacotherapy was with combination
buprenorphine/naloxone. The mean dose of buprenor-
phine (+ S.D.) was 10.32 + 7.89 mg/d.
Laboratory parameters
Table 3 lists the laboratory parameters of the two groups.
90% vs. 18% had serological evidence of previous Hepa-
titis C infection (Fisher Exact Test P = 0.00190, O.R. =
40.50, 95% C.I. 2.36–1963.44). There was however no
difference in the rate of abnormal alanine aminotrans-
ferase (ALT; 40% vs. 18% Fisher Exact Test = 0.361) nor its
mean value (see Table 3 61.30 + 61.20 vs. 31.33 + 31.28
df = 17, Student's T = -1.32, P = 0.20). No patients were
HIV positive.
It was of interest that the serum iron (40.9+2.69 vs.
45.22+2.82 Student's T = 2.26, df = 17, P = 0.037) and the
mean corpuscular volume (87.00+2.58 vs. 92.33+2.96 fl
Student's T = 4.19, df = 17, P = 0.00061) were lower in the
SUD group, despite the higher rate of females in the N-
SUD group. The five females in the control group were all
post-menopausal (mean ages 63.2+15.1 years). The albu-
min (40.90+2.69 vs. 45.22+2.82 Student's T = 3.42, df =
17, P= 0.00325) and cholesterol (4.26+1.09 vs. 5.51+0.95
Student's T = 2.65, df = P = 0.016) were also lower in the
SUD group, suggesting a possible nutritional contribu-
tion. It should also be noted that differences between the
groups in serum iron levels disappeared on non-paramet-
ric testing (Wilcoxson's, Friedman and Sign tests all non-
significant), and the Friedman and Sign test were non-sig-
nificant for cholesterol alterations (Wilcoxson's T = 3.00,
Z = 2.100, P = 0.036).
However the triglyceride and blood glucose levels were
not different in the two groups (by all four tests).
Haematological Values
Haematological values are listed in Table 3 and illustrated
graphically in Figure 1. Detailed information relating to
ranges of these parameters is given in Table 4. As demon-
strated in Table 3, there is no significant difference in most
of these parameters. Data relating to the MCV and iron
levels was mentioned above.
Absolute lymphocyte (2.23+0.67 vs. 2.12 + 0.78 × 109/l,
Student's T = -0.35, df = 19, P = 0.73) and mononuclear
(2.76+0.86 vs. 2.18+1.43 × 109/l Student's T = -1.10, df =
19, P = 0.28) counts were similar (Table 3) as were their
ranges (Table 4). Haemopoietic stem cells (HS's) were not
different in the two groups (2.38+1.09 Vs. 3.40+4.56
cells/mcl, Student's T = 1.72, df = 19, P = 0.10). Endothe-
lial progenitor cells (EPC's) were lower in the SUD
(0.09+0.14 Vs. 0.26+0.20 cells/mcl, Student's T = 2.25, df
= 19, P = 0.0367) both by absolute counts, and when
numbers with EPC counts less than 0.15 × 1011 were con-
sidered (Fisher Exact Test = 0.0299, Yates corrected Chi
Table 1: Demographic data
Variable SUD Non-SUD P*
Age 36.20 (8.61) 56.36 (18.56) 0.00543
% Male 100% 55% 0.03508
Height 179.30 (11.61) 169.82 (8.22) 0.04228
Weight 76.70 (13.53) 75.64 (18.16) 0.88003
BMI 23.77 (2.79) 26.00 (4.47) 0.18506
BP Systolic 115.00 (9.72) 119.67 (14.76) 0.43506
BP Diastolic 70.50 (5.99) 74.44 (11.30) 0.36820
Vasculopathy 20% 18% 1.00000
Data as Mean (+ S.D.).
Statistical Tests – Student's T-test for continuous variables;
Fisher Exact test (2 tailed) for categorical variablesSubstance Abuse Treatment, Prevention, and Policy 2007, 2:19 http://www.substanceabusepolicy.com/content/2/1/19
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Table 2: Drug use data
SUD Non-SUD P* O.R. (95%C.I.)/(Details)
CATEGORICAL DATA – RELATIVE FREQUENCIES
Tobacco Use 80% 18% 0.01431 18.00 (1.50–265.16)
Alcohol Use 0% 27% 0.83270 0.00 (0.00–2.52)
Cannabis Use 90% 18% 0.00815 40.50 (2.36–1963.44)
Amphetamine Use 90% 18% 0.00815 40.50 (2.36–1963.44)
Heroin 100% 0% 0.00157 Not Defined
Methadone Use 30% 9% 0.3107 4.29 (0.26–247.01)
QUANTITATIVE USE DATA
Cigarettes (/day) 14.70 (10.21) 3.64 (8.09) 0.00468 (df = 19; T = -2.7657)
Heroin Dose (g/day) 0.55 (0.34) 0.07 (0.16) 0.00157 (df = 19; T = -5.3803)
Duration Opiate Addiction (Yrs) 12.70 (7.10) 3.55 (8.41) 0.01141 (df = 19; T = -2.6805)
Data as Mean (+ S.D.).
* – Statistical Tests – Student's T-test for continuous variables;
Fisher Exact test (2 tailed) for categorical variables
Table 3: Laboratory parameters
SUD Non-SUD P*
Serolgy
HCV+ 90% 18% 0.00190
HIV + 0% 0% -
Biochemistry
ALT (Iu/l) 61.30 (61.20) 31.33 (31.28) 0.20451
RAISED ALT 40% 18% 0.36145
Iron (mcmol/l) 40.9 (2.69) 45.22 (2.82) 0.03711
Albumin (/l) 40.90 (2.69) 45.22 (2.82) 0.00325
Cholestrol(mmol/l) 4.26 (1.09) 5.51 (0.95) 0.01685
Triglyceride (mmol/l) 1.40 (0.63) 1.40 (.57) 1.00000
BSL (mmol/l) 5.63(2.22) 4.57 (0.80) 0.18239
Haematology
Haemoglobin(g/l)1 140.9(11.96 148.78(12.38)
MCV(fl) 87.00 (2.58) 92.33 (2.96) 0.00061
PP (x109/l) 258.10 (77.44) 286.89 (79.57) 0.43637
WCC (x109/l) 6.58 (2.42) 7.39 (2.12) 0.44777
Lymphocytes (x109/l) 2.23 (0.67) 2.12 (0.78) 0.72715
Monocytes (x109/l) 0.53 (0.24) 0.59 (0.26) 0.61419
Mononuclear Cells 
(x109/l)
2.76 (0.86) 2.18 (1.43) 0.27302
Neutrophils (x109/l) 3.58 (1.78) 4.41 (1.40) 0.27079
CD34+/CD45+ (x1011/
l)
2.38 (1.09) 3.40(4.56) 0.10166
CD34+/KDR+ (x1011/l) 0.09 (0.14) 0.26 (0.20) 0.03674
Data as Mean (+ S.D.)
Statistical Tests – Student's T-test for continuous variables;
Fisher Exact test (2 tailed) for categorical variables
Squared 0.047, df = 1, O.R. = 0.09, C.I. 0.01–0.97) not-
withstanding the significantly older age of the N-SUD
group. The interpretation of these differences is, of course,
complicated by the difference in ages between the two
groups. Nevertheless, there is much published evidence
that both HSC's and EPC's tend to decline with age[25].
The higher mean age of the control sample is therefore
likely to result in an under-estimate of any effect of drug
addiction on HSC's or EPC's.
Figure 1A shows the relationship of the lymphocyte
counts with age in both addicted and non-addicted
groups. When a linear model is fitted to these data
(including SUD/N-SUD effects, a linear age effect, and a
group by age interaction) the group by age interaction is
not statistically significant. An approximate analysis was
conducted, using a lowess[30] fit of EPC and HSC to age,
for each group, and a common lowess fit to both groups.
An approximate F statistic approached significance (P =
0.07), indicating weak evidence in favour of a different
relationship between age and both HSC and EPC for the
SUD and N-SUD groups – with the SUD group having
lower numbers of both HSC's and EPC's compared with
NA group members of equivalent age. This analysis is pre-
liminary, and should be confirmed by further studies with
larger sample sizes before the conclusion can be consid-
ered robust.
Figure 1B depicts similar data when a single outlier has
been excluded. Confirmation that there is a different rela-
tionship in addicted and non-addicted patients' total lym-
phocyte counts with age has been submitted for
publication in a large group of patients31,but the effect is
quantitatively mild. Indeed in a group of 377 addicts and
2748 controls, the mean lymphocyte counts were
2.41(+0.03) and 2.26(+0.01), or only a 6.6% difference
which does not alone explain the observed difference in
progenitor cell counts. Figure 1C shows a clear separation
of the HSC counts by age in the two groups which is
emphasized when ellipses set at 95% confidence intervals
are included (Figure 1D). Figure 1E shows similar data for
EPC's with age, and Figure 1F shows the separation of the
two groups shown by ellipse fitting at the C.I.'s. For bothSubstance Abuse Treatment, Prevention, and Policy 2007, 2:19 http://www.substanceabusepolicy.com/content/2/1/19
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Hematological parameters by age Figure 1
Hematological parameters by age.: A: Lymphocyte count; B: Lymphocyte Count, Single outlier excluded; C: Haemopoetic 
Stem Cells; D: Haemopoetic Stem Cells with ellipses at 95% confidence intervals ; E: Endothelial progenitor cells (EPC's); F: 
EPC's with two outliers excluded and C.I. Ellipses.
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HSC's and EPC's there appeared to be a decline with age
which was more marked in the addict group.
The significance testing of these various comparisons was
little changed if non-parametric statistical tests (Friedman
ANOVA, Wilcoxson matched pairs and Sign test) were
applied to these studies. A detailed analysis for the bivari-
ate Friedman ANOVA test is summarized in Table 5.
Discussion
These data are significant as they are the first to our knowl-
edge to interrogate the issue which is believed to be
important in both the biology of ageing and addiction
medicine in relation to the changes in circulating stem cell
numbers which occur with age. They demonstrate a proof
of principal effect that such changes can be studied in
addicted patients and potentially interesting and impor-
tant conclusions can be drawn. Having said that present
data are admittedly preliminary only. Whilst they clearly
invite further investigation in many different respects, it is
important not to overstate the implications which can
realistically be made from such an initial pilot report.
These data are notable because they suggest a clear separa-
tion between addicts and controls in both the general hae-
mopoietic and the endothelial stem cell progenitors
which achieves statistical significance in the case of the
EPC's. In fact the degree of separation of the two groups is
more marked than in any other dataset on addiction to
our knowledge. Based on the data presented the decline in
stem cells circulating in the peripheral blood appears to be
three or four times as fast in addicts as in the general pop-
ulation. It also seems noteworthy to us that statistical sig-
nificance has been reached with such small datasets. This
fact together with the obvious separation of the two
groups on graphical analysis suggests that the effect is
both real and potentially important. Therefore our data,
although clearly preliminary, are consistent with pub-
lished data suggesting impaired cell growth and potentia-
tion of apoptosis due to addictive drugs[1-3]. As noted in
the presentation of the results some of our data (margin-
ally lower iron, cholesterol and albumin in SUD) is per-
haps consistent with a nutritional contribution to this
effect; however the triglyceride and blood sugar data was
not different between the two groups. Cholesterol and
albumin are well known to have an hepatic synthetic con-
tribution to their serum levels and alterations of liver
function are well known in populations of SUD using
drugs by the intravenous route (although they were not
demonstrated in this study).
Should these early results be confirmed more generally by
further studies with larger patients numbers and addi-
tional cell lines (including presently developmental neu-
rogenesis imaging techniques[32-34]), these findings
have very significant potential implications for under-
Table 5: Non-paramertic significance testing Friedman ANOVA 
results
Nd f C h i  
Square
Coefficient of 
cncordance
P
Age 10 1 6.400 0.640 0.01141
Height 10 1 5.444 0.544 0.01963
Weight 10 1 0.400 0.400 0.52709
Body Mass Index 10 1 1.600 0.160 0.20590
BP Systolic 8 1 0.200 0.025 0.65472
BP Diastolic 8 1 1.000 0.125 0.31731
Cholesterol 8 1 2.000 0.250 0.15730
Triglycerides 8 1 0.000 0.000 1.00000
BSL 8 1 0.500 0.625 0.47950
HCV 10 1 7.000 0.700 0.00815
ALT 8 1 3.571 0.446 0.05878
Iron 8 1 1.285 0.160 0.25684
Albumin 8 1 4.500 0.562 0.03390
Cigarettes 10 1 8.000 0.800 0.00468
Cigs +/- 10 1 6.000 0.600 0.01431
Alcohol 10 1 3.000 0.272 0.83270
Cannabis 10 1 7.000 0.700 0.00815
Amphetamine 10 1 7.000 0.700 0.00815
Heroin 10 1 10.000 1.000 0.00157
Opiate Years 10 1 6.400 0.640 0.01141
Haemoglobin 10 1 6.400 0.640 0.01141
MCV 8 1 4.500 0.562 0.03390
Platelets 8 1 0.500 0.063 0.47950
WCC 8 1 2.000 0.250 0.15730
Lymphocytes 10 1 1.600 0.160 0.25090
Monocytes 8 1 0.000 0.000 1.00000
Mononuclears 10 1 1.600 0.160 0.20590
Neutrophils 8 1 0.500 0.063 0.47950
HSC's 10 1 0.500 0.050 0.47950
Table 4: Laboratory data ranges. Ranges: minimum-maximum
SUD Non-SUD
Biochemistry
ALT (IU/l) 13–193 10–105
Iron 5–21 11–23
Albumin 38–46 41–49
Cholesterol 2.8–6.4 4.1–7.0
Triglyceride 0.6–2.5 0.5–2.1
BSL 3.8–11.1 3.5–6.0
Haematology
Haemoglobin 121–157 126–166
MCV 82–90 88–98
Platelets 188–404 148–396
WCC 4.00–12.10 5.30–11.80
Lymphocytes 1.60–3.50 1.00–3.40
Monocytes 0.20–1.00 0.40–1.20
Mononuclears 1.80–4.50 0.00–4.40
Neutrophils 1.80–7.50 2.90–7.10
CD34+CD45+ - HSC's 1.00–4.00 1.00–6.00
CD34+/KDR+ - EPC's 0.00–0.40 0.00–0.70Substance Abuse Treatment, Prevention, and Policy 2007, 2:19 http://www.substanceabusepolicy.com/content/2/1/19
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standing the cumulative toxicology of indefinite mainte-
nance therapies and programmes both for opiate
dependency, and, because other addictive drugs have sim-
ilar cytostatic effects, the notion presently widespread in
medicinal chemistry, clinical, research funding and other
circles that agonist medication is functionally superior to
sustain patient compliance in the long term to antago-
nists, for the whole direction of the development of the
much needed adjuctive pharmacotherapies for other
chemical dependencies. If confirmed the present results
are likely to have far reaching implications for clinical
practice and hence public policy, particularly as an
increasing number of long acting depot preparations of
antagonists are currently entering the marketplace[35,36].
Hence this preliminary study suggests further lines of
investigation for on-going research in this important field,
with significant future implications for drugs policy
administrations and long term patient treatment develop-
ment.
These findings achieve particular significance in the light
of landmark papers suggesting remarkable prognostic sig-
nificance particularly to the endothelial stem cell count as
a predictor of cardiovascular risk and long term out-
come[25]. This is underscored by the unusual morbidity
and mortality well known to be associated with drug
addiction, and strongly suggests that other mechanisms
may be involved in the clinical features of addiction in
addition to the usually described toxicities such as respira-
tory depression and co-occurring mental illness. They sug-
gest also that, if this reduction represents in fact a
generalized defect of cell renewal, it may be an important
factor underlying the widely recognized elevated mortal-
ity of drug addiction, which in some series has been
reported to be 10–70 times that of non-clinical popula-
tions[37,38]. Clinical evidence in relation to hair greying,
that a generalized defect of pigmentary stem cells likely
exists right across the scalp, was recently reported from
this clinic[20].
The present dataset does not allow dissection of the major
chemical – or for that matter lifestyle – factor/s which
might be responsible for the observed dramatic deficit in
circulating progenitor cells, but this is clearly an impor-
tant point for further clinical and laboratory studies.
The techniques of flow cytometry lend themselves to the
simultaneous testing of these concepts in multiple circu-
lating stem and progenitor cell lines. In addiction to the
two lines studied here, monoclonal antibodies directed
against bone alkaline phosphatase and osteocalcin (for
osteoblastic progenitors[39]), cytokeratin 5 and chemok-
ine CXCR4 (for epithelial progenitors[40]) and oil red O
staining (for adipogenic progenitors[41]) have been
described. Indeed molecular parameters of ageing in such
stem cells[42] can also be quantified by applying appro-
priate monoclonal antibodies in flow cytometric assays.
The availability of techniques for stem and progenitor
cells of many tissue specificities suggests that this tech-
nique lends itself to expansion of use with stem cells from
multiple tissue lineages and formal quantitation of the
pro-ageing hypothesis. Combination of flow cytometry
with cell sorting will allow other techniques to be applied
including tests of stem cell function including replicative
limits, genetic and chromosomal integrity, susceptibility
to oxidative stress, mitochondrial function and biogen-
esis, and molecular markers of ageing (including
p16INK4A, p15INK4B, p16ARF, Bmi1, Dec1, Mcl1, DcR2,
acidic  β-galactosidase, telomere length and hetero-
chromatin foci) [42-45]. Such studies are planned in our
laboratories in the near future.
If addictive agents impair cell regeneration and potentiate
cell death and senescence pathways in vivo as has been
suggested in vitro, this carries obvious implications for the
long term health impacts of SUD patients. If however, this
regenerative defect occurs in the presence of addiction
induced disordered DNA repair and elevated DNA replica-
tion error rates and major chromosomal translocation
and non-disjunction errors as have been noted46, then
with further investigations, the implications of addiction
for cell regeneration both quantitatively and qualitatively,
may prove to be profound indeed. Cancer is well known
to be part of the spectrum of disorders which become
increasingly common with age[11], and has also been
described in addiction[47]. Many oncogenic molecular
pathways exist in addiction[46,48-50]. Furthermore at the
cellular level there are increasing pathways described
between cellular senescence and growth arrest on the one
hand and oncogenesis on the other[42,51]. If disruption
of the integrity of DNA replication and repair mechanisms
is demonstrated by relevant assays, the impact of disor-
dered tissue regeneration as suggested by the present
results would be amplified.
Furthermore it is important to note that these results also
suggest interesting parallels between addiction and the
ageing process which may well prove a fruitful line of
investigation for both fields of bioscientific investigation.
This study carries significant proof of concept implica-
tions in several medical disciplines including addiction,
the biology of ageing and clinical toxicology, and has pub-
lic policy implications both for drugs policy administra-
tion and preferred patient treatments. That is to say that at
the level of patient treatment, indefinite maintenance ago-
nist treatment as is commonly advocated for opiate and
other addictions may have to be re-considered; indeed the
basic toxicology of addiction itself may have been signifi-
cantly underestimated. Should such results be confirmedSubstance Abuse Treatment, Prevention, and Policy 2007, 2:19 http://www.substanceabusepolicy.com/content/2/1/19
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by larger scale more detailed investigations, such results
invite a careful review of the evidentiary basis of the drugs
policy debate. Better understanding of the molecular
pathophysiological mechanisms responsible could
improve our understanding of the biology of ageing, lead
to new ways of investigating common age related disor-
ders, and suggest new paths to treatment development. If
cell regeneration in addiction is not just suppressed but
disorganized this has further implications for expanding
our understanding of addiction-related, heritable and
other oncogenesis.
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